Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at D. Boral Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $18.00 price objective on the stock. D. Boral Capital's price objective indicates a potential upside of 173.56% from the stock's current price.
Separately, Chardan Capital reiterated a "buy" rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, March 20th.
Get Our Latest Stock Analysis on COYA
Coya Therapeutics Trading Up 0.3 %
COYA stock traded up $0.02 during trading on Thursday, reaching $6.58. The stock had a trading volume of 16,586 shares, compared to its average volume of 70,288. The firm has a market cap of $110.05 million, a PE ratio of -10.12 and a beta of 0.31. The stock's 50 day moving average is $6.43 and its two-hundred day moving average is $6.52. Coya Therapeutics has a 52 week low of $4.75 and a 52 week high of $10.24.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.14. The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.10 million. On average, research analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current year.
Institutional Investors Weigh In On Coya Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in COYA. Geode Capital Management LLC raised its holdings in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company's stock valued at $918,000 after acquiring an additional 4,485 shares during the period. Newbridge Financial Services Group Inc. purchased a new stake in shares of Coya Therapeutics during the fourth quarter worth about $401,000. CM Management LLC raised its stake in Coya Therapeutics by 11.1% during the 4th quarter. CM Management LLC now owns 160,000 shares of the company's stock valued at $917,000 after purchasing an additional 15,941 shares during the period. AIGH Capital Management LLC raised its stake in Coya Therapeutics by 85.0% during the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company's stock valued at $6,883,000 after purchasing an additional 551,725 shares during the period. Finally, XTX Topco Ltd purchased a new position in Coya Therapeutics in the 4th quarter worth approximately $59,000. Institutional investors own 39.75% of the company's stock.
About Coya Therapeutics
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Featured Stories
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
